CDSCO Panel Approves Pfizer's Protocol Amendment Proposal to Study Aztreonam and Avibactam

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major Pfizer to study Aztreonam and Avibactam compared to the best available therapy for serious gram-negative infections.

This came after the firm presented protocol amendment 3 dated 10 June 2024 protocol No. C3601008. The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants.

Aztreonam is the first member of a new class of beta-lactam antibiotics, the monobactams. Azitreonam is selectively active against Gram-negative aerobic bacteria and inactive against Gram-positive bacteria.

The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis.

Avibactam is a novel non-β-lactam β-lactamase inhibitor that inhibits a wide range of β-lactamases. These include class A, class C, and some class D enzymes, which erode the activity of β-lactam drugs in multidrug-resistant pathogens like Pseudomonas aeruginosa and Enterobacteriaceae spp.

The mechanism of β-lactamase inhibition used by avibactam is similar to that of previous β-lactamase inhibitors. Through covalent binding of the β-lactamase active site hydroxyl group, avibactam diminishes the availability of active enzyme for hydrolysis and thus decreases inactivation of the β-lactam antibiotic.

At the recent SEC meeting for antimicrobials and antivirals held on 22nd August 2024, the expert panel reviewed protocol amendment 3 dated 10 June 2024 protocol No. C3601008 presented by the drug major Pfizer.

After detailed deliberation, the committee recommended approval of the protocol amendment as presented by the firm.

Also Read: MSN Laboratories gets CDSCO Panel nod to conduct Bioequivalence Study of Abiraterone Tablets1000mg



from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/JSl2hPH

Comments

Post a Comment

Popular posts from this blog

'Details sought include Third-party info, hence exempted under RTI Act': NMC on RTI query on Faculty Gap in Medical Colleges

Image
New Delhi:  Stating that the details sought under the RTI includes third-party information, the National Medical Commission (NMC) has refused to disclose the names of the medical colleges that fell short on faculty counts and other teaching infrastructure. Recently activist Dr. KV Babu filed an application under the Right to Information Act seeking the details of the notices issued by the NMC Undergraduate Medical Education Board (UGMEB) to the medical colleges for deficiencies in Clinical Material and staff during the period from 01/01/2023 to 30/04/2024. He also sought to know the details of the fine imposed or the action taken by the NMC UG Board from 01/01/2023 to 30/04/2024. In response, the Apex medical regulatory body in India has said that the concerned information includes third party information. "Since the information sought by you, includes third party information, hence the same is exempted for as per Section 8(1) (j) of the Right to Information Act, 2005," th...
Read more

Zasocitinib therapy highly efficacious for treatment of severe plaque psoriasis: JAMA

Image
A recent study published in the Journal of American Medical Association revealed that Zasocitinib could be a breakthrough in the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin condition characterized by red, scaly patches, affects millions throughout the globe. While several treatments exist, the demand for new, effective, and well-tolerated oral therapies remains high. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, emerges as a promising candidate to meet this need. This trial was conducted between August 2021 and September 2022 across 55 centers in the US and Canada and found that Zasocitinib not only significantly improved skin clearance in patients but also expressed a favorable safety and tolerability profile. The study enrolled a total of 287 participants aged between 18 and 70 years, each with a Psoriasis Area and Severity Index (PASI) score of 12 or greater, a Physician’s Global Assessment score of 3...
Read more

New wearable laser device may monitor brain blood flow to gauge stroke risk, reports research

Image
Researchers have developed a laser-based device that can be placed on the head to non-invasively monitor changes in brain blood flow and volume. The new device could one day help save lives by offering a direct and simple way to assess stroke risk based on physiological markers rather than indirect markers like lifestyle factors. Strokes occur when blood flow to the brain is blocked or reduced, causing debilitating brain cell damage. With about 15 million people worldwide affected by strokes each year, it is the second leading cause of death and a leading cause of long-term disability. “The lack of a cost-effective and scalable stroke risk assessment system complicates long-term stroke prevention because a physician can’t tell whether a patient’s risk is stable or worsening,” said research team member Simon Mahler, a postdoctoral scholar in Changhuei Yang’s laboratory at the California Institute of Technology. “This new method could help catch early signs of increased stroke risk, w...
Read more